Mitotech is a biotechnology company with a portfolio of novel mitochondria-targeted small molecules. Dysfunctional mitochondria are implicated in aging and many neurodegenerative, metabolic and cardiovascular diseases. Mitochondria play critical role in key biological processes, such as mitophagy, oxidative stress, apoptosis and ferroptosis that regulate wellbeing of living cells.

Our core team brings together cross-disciplinary scientific experts, seasoned clinical drug development professionals and experienced business leaders. Using this blend of business skills, industry expertise and fundamental scientific knowledge our company aims to tackle complex scientific problems, such as protection of mitochondria against oxidative stress and countering uncontrolled inflammation, and to turn the company’s innovative research into successful pharmaceutical products. The company’s mission is to leverage its break-through in delivering highly active compounds into mitochondria across a wide spectrum of neurodegenerative and metabolic indications and to provide medicines based on this novel mechanism of action to patients worldwide.